An official website of the United States government
Home
Name
Vanflyta
Alternate Names
Quizartinib
Abbreviations
None
Category
Chemotherapy
Subcategory
tyrosine kinase inhibitor
NSC Number
None
Primary Site
Acute myeloid leukemia
AML
Histology
None
Remarks
July 20, 2023 FDA approved quizartinib (Vanflyta) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test.
Coding
This drug should be coded
